Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92
Summary
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 is a scholarly article[1].
Key Facts
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92's instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. Retrieved May 24, 2026, from https://4ort.xyz/entity/therapeutic-vulnerability-of-multiple-myeloma-to-mir17pti-a-first-in-class-inhibitor-of-pri-mir-17-92
MLA“Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/therapeutic-vulnerability-of-multiple-myeloma-to-mir17pti-a-first-in-class-inhibitor-of-pri-mir-17-92.
BibTeX@misc{4ortxyz_therapeutic-vulnerability-of-multiple-myeloma-to-mir17pti-a-first-in-class-inhibitor-of-pri-mir-17-92_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92}}, year = {2026}, url = {https://4ort.xyz/entity/therapeutic-vulnerability-of-multiple-myeloma-to-mir17pti-a-first-in-class-inhibitor-of-pri-mir-17-92}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 — https://4ort.xyz/entity/therapeutic-vulnerability-of-multiple-myeloma-to-mir17pti-a-first-in-class-inhibitor-of-pri-mir-17-92 (retrieved 2026-05-24)
